KMPH - KemPharm Stock Price, News & Analysis

$3.80 0.10 (2.70 %)
(As of 11/24/2017 11:26 AM ET)
Previous Close$3.70
Today's Range$3.70 - $3.80
52-Week Range$2.45 - $5.40
Volume13,400 shs
Average Volume42,280 shs
Market Capitalization$55.70 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.13

About KemPharm (NASDAQ:KMPH)

KemPharm logoKemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMPH
CUSIPN/A

Debt

Debt-to-Equity Ratio-1.92%
Current Ratio7.56%
Quick Ratio7.56%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($3.28) per share
Price / Book-1.16

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($2.64)
Net Income$-16,510,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-53.56%

Miscellaneous

Employees32
Outstanding Shares14,660,000

Frequently Asked Questions for KemPharm (NASDAQ:KMPH)

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How were KemPharm's earnings last quarter?

KemPharm, Inc. (NASDAQ:KMPH) posted its quarterly earnings results on Wednesday, May, 10th. The specialty pharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.21. View KemPharm's Earnings History.

Where is KemPharm's stock going? Where will KemPharm's stock price be in 2017?

4 brokers have issued 1-year target prices for KemPharm's stock. Their predictions range from $7.00 to $13.00. On average, they anticipate KemPharm's share price to reach $9.00 in the next twelve months. View Analyst Ratings for KemPharm.

What are Wall Street analysts saying about KemPharm stock?

Here are some recent quotes from research analysts about KemPharm stock:

  • 1. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (11/16/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 10, 2017, 16:01 ET Date and time of production: August 10, 2017, 16:01 ET Target Price / Valuation Methodology: KemPharm – KMPH Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $7/share for KMPH, assuming a stable timeline for KemPharm’s lead products, KP415, KP201/IR and KP511/ER. Additionally, we assume a KP415 launch in 2020 and KP201/IR and KP511/ER launches in 2021. Our valuation assumes a generic launch against KP201/IR around 2031 and generic launches against KP415 and KP511/ER around 2032. This corresponds with the expiries of composition of matter patents, before any FDA term extensions, for all three products." (8/10/2017)

Who are some of KemPharm's key competitors?

Who are KemPharm's key executives?

KemPharm's management team includes the folowing people:

  • Travis C. Mickle Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 42)
  • Timothy J. Sangiovanni, Principal Accounting Officer, Vice President, Corporate Controller (Age 33)
  • Gordon K. Johnson, Chief Business Officer

When did KemPharm IPO?

(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Who owns KemPharm stock?

KemPharm's stock is owned by a number of of institutional and retail investors. Top institutional investors include DELAWARE STREET CAPITAL MASTER FUND, L.P. (10.00%), Alyeska Investment Group L.P. (6.77%) and C WorldWide Group Holding A S (2.97%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Institutional Ownership Trends for KemPharm.

Who bought KemPharm stock? Who is buying KemPharm stock?

KemPharm's stock was purchased by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S and Alyeska Investment Group L.P.. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Insider Buying and Selling for KemPharm.

How do I buy KemPharm stock?

Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KemPharm's stock price today?

One share of KemPharm stock can currently be purchased for approximately $3.80.

How big of a company is KemPharm?

KemPharm has a market capitalization of $55.70 million. The specialty pharmaceutical company earns $-16,510,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. KemPharm employs 32 workers across the globe.

How can I contact KemPharm?

KemPharm's mailing address is 2500 CROSSPARK ROAD, CORALVILLE IA, 52241. The specialty pharmaceutical company can be reached via phone at 319-665-2575 or via email at [email protected]


MarketBeat Community Rating for KemPharm (KMPH)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for KemPharm (NASDAQ:KMPH)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (136.84% upside)

Consensus Price Target History for KemPharm (NASDAQ:KMPH)

Price Target History for KemPharm (NASDAQ:KMPH)

Analysts' Ratings History for KemPharm (NASDAQ:KMPH)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017Canaccord GenuityReiterated RatingBuy$7.00HighView Rating Details
8/10/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$13.00MediumView Rating Details
6/28/2017Roth CapitalInitiated CoverageBuy -> Buy$8.00HighView Rating Details
5/15/2017Royal Bank Of CanadaReiterated RatingBuy$8.00MediumView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for KemPharm (NASDAQ:KMPH)

Earnings by Quarter for KemPharm (NASDAQ:KMPH)

Earnings History by Quarter for KemPharm (NASDAQ KMPH)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2017Q2 2017($0.63)($0.44)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.63)($0.84)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.70)($0.68)ViewListenView Earnings Details
11/9/2016Q3 2016($0.70)($0.92)ViewListenView Earnings Details
8/10/2016Q2($0.94)($0.58)ViewListenView Earnings Details
5/12/2016Q1($0.56)($0.20)ViewListenView Earnings Details
3/10/2016Q4($0.50)($0.64)ViewListenView Earnings Details
11/12/2015Q315($0.48)($0.68)ViewListenView Earnings Details
8/13/2015Q215($0.47)($0.59)ViewListenView Earnings Details
5/27/2015Q1($0.49)($2.50)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for KemPharm (NASDAQ:KMPH)
2017 EPS Consensus Estimate: ($2.78)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.69)($0.69)($0.69)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.66)($0.66)($0.66)
Q4 20171($0.80)($0.80)($0.80)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for KemPharm (NASDAQ KMPH)

Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 38.29%
Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)
Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)

Insider Trades by Quarter for KemPharm (NASDAQ KMPH)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2017R. Laduane CliftonCFOBuy300$3.78$1,134.00View SEC Filing  
9/14/2017Delaware Street Capital MasterMajor ShareholderBuy325,888$3.27$1,065,653.76View SEC Filing  
8/24/2017Daniel L CohenEVPBuy5,000$2.58$12,900.00View SEC Filing  
8/24/2017Gordon K JohnsonInsiderBuy4,000$2.60$10,400.00View SEC Filing  
6/20/2017Travis C MickleCEOBuy8,000$3.45$27,600.00View SEC Filing  
6/19/2017R. Laduane CliftonCFOBuy275$3.30$907.50View SEC Filing  
5/25/2017Daniel L CohenEVPBuy2,500$4.11$10,275.00View SEC Filing  
3/31/2017Daniel L CohenEVPBuy2,500$4.48$11,200.00View SEC Filing  
3/24/2017R. Laduane CliftonCFOBuy1,000$4.24$4,240.00View SEC Filing  
3/22/2017Travis C MickleCEOBuy2,000$4.10$8,200.00View SEC Filing  
3/20/2017David S TierneyDirectorBuy1,000$4.20$4,200.00View SEC Filing  
11/30/2016Daniel L CohenEVPBuy5,000$3.50$17,500.00View SEC Filing  
9/6/2016Daniel L CohenEVPBuy10,000$4.75$47,500.00View SEC Filing  
8/17/2016Travis C MickleCEOBuy5,000$4.95$24,750.00View SEC Filing  
3/29/2016Travis C MickleCEOBuy2,450$14.57$35,696.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for KemPharm (NASDAQ KMPH)

Source:
DateHeadline
KemPharm, Inc. (KMPH) Downgraded by Zacks Investment ResearchKemPharm, Inc. (KMPH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 19 at 10:00 AM
KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDAKemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
finance.yahoo.com - November 17 at 11:26 AM
KemPharma reports 3Q lossKemPharma reports 3Q loss
www.cnbc.com - November 11 at 3:17 PM
How Much is KemPharm Inc’s (KMPH) CEO Getting Paid?How Much is KemPharm Inc’s (KMPH) CEO Getting Paid?
finance.yahoo.com - November 11 at 3:17 PM
KemPharm Reports Third Quarter 2017 Results and Provides Corporate UpdateKemPharm Reports Third Quarter 2017 Results and Provides Corporate Update
finance.yahoo.com - November 11 at 3:17 PM
KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511
finance.yahoo.com - November 7 at 6:17 AM
KemPharm, Inc. (KMPH) Given Consensus Recommendation of "Buy" by BrokeragesKemPharm, Inc. (KMPH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 5 at 1:52 AM
-$0.69 Earnings Per Share Expected for KemPharm, Inc. (KMPH) This Quarter-$0.69 Earnings Per Share Expected for KemPharm, Inc. (KMPH) This Quarter
www.americanbankingnews.com - November 4 at 9:26 PM
KemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical StudiesKemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies
finance.yahoo.com - November 3 at 12:53 PM
KemPharm, Inc. to Report Third Quarter 2017 ResultsKemPharm, Inc. to Report Third Quarter 2017 Results
finance.yahoo.com - November 2 at 4:26 AM
KemPharm, Inc. (KMPH) Scheduled to Post Earnings on TuesdayKemPharm, Inc. (KMPH) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:36 AM
KemPharm (KMPH) vs. Its Rivals Head-To-Head SurveyKemPharm (KMPH) vs. Its Rivals Head-To-Head Survey
www.americanbankingnews.com - October 30 at 5:26 PM
KemPharm, Inc. (KMPH) Receives Average Rating of "Buy" from AnalystsKemPharm, Inc. (KMPH) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 11 at 2:50 AM
Featured Company News - KemPharm Signs Technology Licensing Agreement with Genco to Develop Prodrug-Based Therapy for Pediatric Indications of Tourette’s syndrome with ADHDFeatured Company News - KemPharm Signs Technology Licensing Agreement with Genco to Develop Prodrug-Based Therapy for Pediatric Indications of Tourette’s syndrome with ADHD
finance.yahoo.com - October 7 at 1:54 AM
KemPharm (KMPH) and Genco Sciences Announce Pact to Develop Prodrug-Based Therapy for Rare Pediatric Indications of Tourettes Syndrome with ADHDKemPharm (KMPH) and Genco Sciences Announce Pact to Develop Prodrug-Based Therapy for Rare Pediatric Indications of Tourette's Syndrome with ADHD
www.streetinsider.com - October 5 at 7:16 AM
KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHDKemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD
finance.yahoo.com - October 5 at 7:16 AM
 Brokerages Anticipate KemPharm, Inc. (KMPH) Will Announce Earnings of -$0.69 Per Share Brokerages Anticipate KemPharm, Inc. (KMPH) Will Announce Earnings of -$0.69 Per Share
www.americanbankingnews.com - September 27 at 4:30 PM
KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of MethylphenidateKemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate
finance.yahoo.com - September 21 at 12:29 PM
KemPharm, Inc. (KMPH) Earns Buy Rating from Canaccord GenuityKemPharm, Inc. (KMPH) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - September 17 at 10:22 PM
KemPharm, Inc. (KMPH) Given Average Rating of "Buy" by BrokeragesKemPharm, Inc. (KMPH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 16 at 3:10 AM
KemPharm, Inc. (KMPH) Major Shareholder Delaware Street Capital Master Acquires 325,888 SharesKemPharm, Inc. (KMPH) Major Shareholder Delaware Street Capital Master Acquires 325,888 Shares
www.americanbankingnews.com - September 15 at 4:30 PM
Astellas, KMPH, SRNE To Face FDA, ALXN Trims Workforce, ALDX Soars On Trial DataAstellas, KMPH, SRNE To Face FDA, ALXN Trims Workforce, ALDX Soars On Trial Data
www.rttnews.com - September 13 at 3:33 AM
KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDAKemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA
finance.yahoo.com - September 13 at 3:33 AM
KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceKemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 1 at 1:55 AM
KemPharm, Inc. (KMPH) Insider Buys $10,400.00 in StockKemPharm, Inc. (KMPH) Insider Buys $10,400.00 in Stock
www.americanbankingnews.com - August 25 at 8:54 PM
KemPharm, Inc. (KMPH) EVP Daniel L. Cohen Buys 5,000 SharesKemPharm, Inc. (KMPH) EVP Daniel L. Cohen Buys 5,000 Shares
www.americanbankingnews.com - August 25 at 8:54 PM
KemPharm, Inc. (KMPH) Given Consensus Rating of "Buy" by BrokeragesKemPharm, Inc. (KMPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 22 at 2:58 AM
KemPharm, Inc. (KMPH) Expected to Announce Earnings of -$0.69 Per ShareKemPharm, Inc. (KMPH) Expected to Announce Earnings of -$0.69 Per Share
www.americanbankingnews.com - August 21 at 6:14 AM
KemPharm, Inc. (KMPH) Given a $13.00 Price Target at Oppenheimer Holdings, Inc.KemPharm, Inc. (KMPH) Given a $13.00 Price Target at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - August 13 at 6:32 PM
KemPharm (KMPH) Announces Prelim. Results from KP415 Pharmacokinetic Single and Multiple Dose TrialKemPharm (KMPH) Announces Prelim. Results from KP415 Pharmacokinetic Single and Multiple Dose Trial
www.streetinsider.com - August 12 at 1:54 AM
KemPharma reports 2Q lossKemPharma reports 2Q loss
www.cnbc.com - August 12 at 1:54 AM
KemPharm, Inc. (NASDAQ:KMPH) Issues Quarterly  Earnings ResultsKemPharm, Inc. (NASDAQ:KMPH) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 11 at 5:16 PM
KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose TrialKemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial
finance.yahoo.com - August 11 at 5:49 AM
KemPharm, Inc. Reports Second Quarter 2017 ResultsKemPharm, Inc. Reports Second Quarter 2017 Results
finance.yahoo.com - August 11 at 5:49 AM
KemPharms (NASDAQ:KMPH) "Buy" Rating Reaffirmed at Canaccord GenuityKemPharm's (NASDAQ:KMPH) "Buy" Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - August 10 at 6:26 PM
KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug SafetyKemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety
finance.yahoo.com - August 8 at 7:59 PM
KemPharm to Present at Canaccord Genuity 37th Annual Growth ConferenceKemPharm to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 11:31 PM
KemPharm, Inc. to Report Second Quarter 2017 ResultsKemPharm, Inc. to Report Second Quarter 2017 Results
finance.yahoo.com - August 2 at 2:46 AM
KemPharm, Inc. (NASDAQ:KMPH) Receives Average Rating of "Buy" from BrokeragesKemPharm, Inc. (NASDAQ:KMPH) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 28 at 11:21 AM
KemPharm, Inc. (KMPH) Receives Consensus Recommendation of "Hold" from BrokeragesKemPharm, Inc. (KMPH) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 3 at 12:04 PM
KemPharm, Inc. (KMPH) Now Covered by Roth CapitalKemPharm, Inc. (KMPH) Now Covered by Roth Capital
www.americanbankingnews.com - July 2 at 3:08 PM
KemPharm (KMPH) Announced Two Advances Involving its Prodrug Development Pipeline to Treat ADHDKemPharm (KMPH) Announced Two Advances Involving its Prodrug Development Pipeline to Treat ADHD
www.streetinsider.com - June 30 at 12:52 AM
KemPharm (KMPH) Granted First Patent for KP746KemPharm (KMPH) Granted First Patent for KP746
www.streetinsider.com - June 26 at 8:05 PM
KemPharma reports 1Q lossKemPharma reports 1Q loss
www.cnbc.com - May 10 at 6:06 PM
KEMPHARM, INC Files SEC form 8-K, Changes in Registrants Certifying Accountant, Financial Statements and ExhibitsKEMPHARM, INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
biz.yahoo.com - March 28 at 5:46 PM
KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual MeetingKemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting
us.rd.yahoo.com - March 16 at 6:58 PM
7:32 am KemPharm presents data on KP511 and KP201/IR at the American Academy of Pain Medicine Annual Meeting7:32 am KemPharm presents data on KP511 and KP201/IR at the American Academy of Pain Medicine Annual Meeting
us.rd.yahoo.com - March 16 at 6:58 PM
KEMPHARM, INC Files SEC form 10-K, Annual ReportKEMPHARM, INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 10 at 7:23 PM
KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results - GlobeNewswire (press release)KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results - GlobeNewswire (press release)
globenewswire.com - March 10 at 7:57 AM
KemPharm, Inc. Reports Fourth Quarter and Year End 2016 ResultsKemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results
us.rd.yahoo.com - March 9 at 9:06 PM

Social Media

Financials

Chart

KemPharm (NASDAQ KMPH) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.